Development of nano alpha-ketoglutarate nebulization formulation and its pharmacokinetic and safety evaluation in healthy human volunteers for cyanide poisoning

Environmental Toxicology and Pharmacology

Volumn 31, Issue 3, 2011, Pages 436-442

  Sultana, Shaheen ^a   Singh, Thakuri ^b   Ahmad, Farhan Jalees ^a   Bhatnagar, Aseem ^b   Mittal, Gaurav ^b  

^a HAMDARD UNIVERSITY   (India)

^b INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

Author keywords

Alpha ketoglutarate; Cyanide poisoning; Nebulization; Pharmacoscintigraphy

Indexed keywords

2 OXOGLUTARIC ACID; ALCOHOL; HYDROGEN CYANIDE; SODIUM CHLORIDE; TECHNETIUM 99M;

ADULT; AEROSOL; AREA UNDER THE CURVE; ARTICLE; BREATHING MECHANICS; CONTROLLED STUDY; CYANIDE POISONING; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG SAFETY; FIRE FIGHTER; GAMMA SCINTIGRAPHY; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALE; MAXIMUM PLASMA CONCENTRATION; NEBULIZATION; NORMAL HUMAN; PARTICLE SIZE; PRIORITY JOURNAL; VOLUNTEER;

ADULT; AREA UNDER CURVE; CHEMISTRY, PHARMACEUTICAL; CYANIDES; ETHANOL; HUMANS; ISOTOPE LABELING; KETOGLUTARIC ACIDS; LUNG; MALE; NANOPARTICLES; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; RESPIRATORY FUNCTION TESTS; SOLVENTS; TECHNETIUM;

EID: 79954961321     PISSN: 13826689     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.etap.2011.02.005     Document Type: Article

References (38)

1. Ali R., Jain G.K., Iqbal Z., Talegaonkar S., Pandit P., Sule S., Malhotra G., Khar R.K., Bhatnagar A., Ahmad F.J. Development and clinical trial of nano-atropine sulfate dry powder inhaler as a novel organophosphorous poisoning antidote. Nanomedicine NBM. 2009, 5:55-63.
2. Ballantyne B. The influence of exposure route and species on the acute lethal toxicity and tissue concentrations of cyanide. Dev. Toxicol. Environ. Sci. 1983, 11:583-586.
3. Baskin S.L., Horowitz A.M., Nealley E.W. The antidotal action of sodium nitrite and sodium thiosulphate against cyanide poisoning. J. Clin. Pharmacol. 1992, 32:368-375.
4. Baud F.J. Cyanide: critical issues in diagnosis and treatment. Hum. Exp. Toxicol. 2007, 26:191-201.
5. Beasley D.M.G., Glass W.I. Cyanide poisoning: pathophysiology and treatment recommendations. Occup. Med. 1998, 4:427-431.
6. Beatriz M.M. Hydroxocobalamin: New antidote for cyanide poisoning. Pharm. Today 2007, 24-25.
7. Bhattacharya R. Antidotes to cyanide poisoning: present status. Ind. J. Pharmacol. 2000, 32:94-101.
8. Bhattacharya R., Vijayaraghavan R. Promising role of α-ketoglutarate in protecting the lethal effects of cyanide. Hum. Exp. Toxicol. 2002, 21:297-303.
9. Bhattacharya R., Tulsawani R.K. In vitro and in vivo evaluation of various carbonyl compounds against cyanide toxicity with particular reference to alpha-ketoglutaric acid. Drug Chem. Toxicol. 2008, 31:149-161.
10. Bhavna, Ahmad F.J., Mittal G., Jain G.K., Malhotra G., Khar R.K., Bhatnagar A. Nano-salbutamol dry powder inhalation: a new approach for treating broncho-constructive conditions. Eur. J. Pharm. Biopharm. 2009, 71:282-291.
11. Boissinot E., Le Pape A., Palmer L., Lemarie E. Aerosols and antiinfectious agents. J. Aerosol Med. 2001, 14:55-64.
12. Borowitz J.L., Isom G.E., Baskin S.I. Acute and Chronic Cyanide Toxicity 2001, 301-319. Chemical Warfare Agents: Toxicity at Low Levels CRC, USA. S.M. Somani, J.A. Romano (Eds.).
13. Coates A.L., MacNeish C.F., Meisner D., Kelemen S., Thibert R., MacDonald J., Vadas E. The choice of jet nebulizer, nebulizing flow and the addition of Ventolin respiratory solution affects tobramycin aerosols used in cystic fibrosis. Chest 1997, 111:1206-1212.
14. Dennis J.H., Stenton S.C., Beach, Avery A.J., Walters E.H., Hendrick D.J. Jet and ultrasonic nebulizer output: use of a new method for direct measurement of aerosol output. Thorax 1990, 45:728-732.
15. Dequin P.F., Faurisson F., Lemarie E., Delatour F., Marchand S., Valat C., Boissinot E., de Gialluly C., Diot P. Urinary excretion reflects lung deposition of aminoglycoside aerosols in cystic fibrosis. Eur. Respir. J. 2001, 18:316-322.
16. DesLauriers C.A., Burda A.M., Wahl M. Hydroxocobalamin as a cyanide antidote. Am. J. Therap. 2006, 13:161-165.
17. Gaur P.K., Mishra S., Gupta V.B., Rathod M.S., Purohit S., Savla B.A. In situ formation of liposome of rifampicin: better availability for better treatment. Curr. Drug Deliv. 2009, 6:461-468.
18. Hall A.H., Saiers J., Baud F. Which cyanide antidote. Rev. Toxicol. Crit. 2009, 39:541-552.
19. Jones K.R., Scott C.M. Hydroxocobalamin (Cyanokit): a new antidote for cyanide toxicity. Adv. Emerg. Nurs. J. 2008, 30:112-121.
20. Kleinstreuer C., Zhang Z., Donohue J.F. Targeted drug-aerosol delivery in the human respiratory system. Ann. Rev. Biomed. Eng. 2008, 15:195-220.
21. Maduh, E.U., 1989. Mechanism of cyanide neurotoxicity. Ph.D. Thesis submitted to Purdue University, IN, USA, pp. 1-199.
22. Mittal G., Singh T., Kumar N., Bhatnagar A., Tripathi R.P., Tulsawani R., Vijayaraghavan R., Bhattacharya R. Radiolabeling and dose fixation study of oral alpha-ketoglutarate as a cyanide antidote in healthy human volunteers. Clin. Toxicol. (Phila) 2010, Jun 23 (Epub ahead of print).
23. Newman S.P., Clark A.R., Talalee N., Clarke S.W. Pressurised aerosol deposition in the human lung with and without an open spacer. Thorax 1989, 44:706-710.
24. Newman S.P., Pellow P.G.D., Clarke S.W. Efficient nebulisation of powdered antibiotics. Int. J. Pharm. 1986, 36:55-60.
25. Newman S.P., Wilding I.R., Hirst P.H. Human lung deposition data: the bridge between in vitro and clinical evaluations for inhaled drug products. J. Pharm. Int. 2000, 208:49-60.
26. Pailla K., Blonde-Cynober F., Aussel C., De Bandt J.P., Cynober L. Branched-chain keto-acids and pyruvate in blood: Measurement by HPLC with fluorimetric detection and changes in older subjects. Clin. Chem. 2000, 46:848-853.
27. Patel R.S., Poddar S.S. Development and characterization of mucoadhesive buccal patches of salbutamol sulphate. Curr. Drug Deliv. 2009, 6:140-144.
28. Perkins A.C., Frier M. Radionuclide imaging in drug development. Curr. Pharm. Des. 2004, 10:2907-2921.
29. Pitcairn G.R., Newman S.P. Tissue attenuation corrections in gamma scintigraphy. J. Aerosol Med. 1997, 10:187-198.
30. Rajpal S., Ali R., Bhatnagar A., Bhandari S.S., Mittal G. Clinical and bioavailability studies of sublingually administered atropine sulphate. Am. J. Emerg. Med. 2010, 28:143-150.
31. Rajpal S., Mittal G., Sachdeva R., Chhillar M., Ali R., Agrawal S.S., Kashyap R., Bhatnagar A. Development of atropine sulphate nasal drops and its pharmacokinetic and safety evaluation in healthy human volunteers. Environ. Toxicol. Pharmacol. 2009, 27:206-211.
32. Sham J.O., Zhang Y., Finlay W.H., Roa W.H., Raimar L. Formulation and characterization of spray dried powders containing nanoparticles for aerosol delivery to the lung. Int. J. Pharm. 2004, 269:457-467.
33. Silkstone V.L., Corlett S.A., Chrystyn H. Determination of the relative bioavailability of salbutamol to the lungs and systemic circulation following nebulization. Br. J. Clin. Pharmacol. 2002, 54:115-119.
34. Singh A.K., Verma J., Bhatnagar A., Sen S., Bose M. Tc-99m isoniazid: a specific agent for diagnosis of tuberculosis. World J. Nucl. Med. 2003, 2:292-305.
35. Tulsawani R.K., Debnath M., Pant S.C., Kumar O., Prakash A.O., Vijayaraghavan R., Bhattacharya R. Effect of sub-acute oral cyanide administration in rats: Protective efficacy of alpha-ketoglutarate and sodium thiosulfate. Chemico-Biol. Interact. 2005, 156:1-12.
36. Tulsawani R.K., Hariharakrishnan J., Jatav P.C., Bhattacharya R. Effects of α-ketoglutarate on some hepatic variables altered by cyanide in vivo and in vitro. J. Cell Tissue Res. 2006, 6:719-725.
37. Van Heijst A.N.P., Douze J.M.C., van Kesteren R.G., van Bergen J.E.A.M., van Dijk A. Therapeutic problems in cyanide poisoning. Clin. Toxicol. 1987, 25:383-398.
38. Vick J.A., Bredow V. Effectiveness of intramuscularly administered cyanide antidotes on methaemoglobin formation and survival. J. Appl. Toxicol. 1998, 16:509-516.